Wang is working on experimental vaccines based on Sars that could bolster the immunity generated by current Covid shots to protect against a broader array of Sars-CoV-2 variants and their virological cousins.
Photo by d3sign/Getty Images
A study by the Singapore Eye Research Institute found low acceptance of digital health services among the elderly.
Supported by the National Medical Research Council, the SERI study aimed to determine COVID-19-related awareness, knowledge, impact and preparedness among elderly Asians. In the process, the study also evaluated acceptance toward digital health services amid the pandemic.
WHAT IT’S ABOUT
Held during Singapore’s lockdown period from 7 April till 1 June 2020, participants comprised 523 citizens from Singapore s three major ethnic groups – Chinese, Indians, and Malays.
Multivariable logistic regression models were performed to evaluate the associations between demographic, socio-economic, lifestyle, and systemic factors, with COVID-19 awareness, knowledge, preparedness, well-being and digital health service acceptance.
Malaysia s Clinical Trials Quagmire asiasentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiasentinel.com Daily Mail and Mail on Sunday newspapers.
The potential benefits of the project lie in being able to quickly and effectively identify the type of drug for patients.. Read more at straitstimes.com.
Vela Diagnostics Announces Collaboration with the National Cancer Centre of Singapore to Refine Novel Cancer Therapy
USA - English
Share this article
Share this article
SINGAPORE, June 3, 2021 /PRNewswire/ Vela Diagnostics announced a collaboration with the National Cancer Centre of Singapore (NCCS) to develop a molecular diagnostic assay to predict individual patients responses to a cancer therapy called Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs). Being able to predict an individual s response will help clinicians determine if EGFR-TKIs are a suitable therapeutic option for the patient. The partnership between Vela Diagnostics and NCCS aims to refine the therapeutic management of cancer to improve clinical outcomes.